Efficacy of topical calcineurin inhibitors in psoriasis

Journal of Cutaneous Medicine and Surgery

Volumn 18, Issue 1, 2014, Pages 8-14

  Wang, Cong ^a   Lin, Andrew ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CALCITRIOL; CLOBETASOL; CLOBETASOL PROPIONATE; CLOBETASONE BUTYRATE; ETRETIN; METHYLPREDNISOLONE ACEPONATE; MOMETASONE FUROATE; PIMECROLIMUS; PLACEBO; SALICYLIC ACID; TACROLIMUS; TAR; VOCLOSPORIN;

COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CREAM; DRUG EFFICACY; FACE; GEL; GENITAL SYSTEM; HUMAN; MONOTHERAPY; NAIL PSORIASIS; OINTMENT; OPEN STUDY; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PUSTULOSIS PALMOPLANTARIS;

CALCINEURIN; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PSORIASIS; TACROLIMUS;

EID: 84892568674     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2013.13059     Document Type: Conference Paper

References (51)

1. Lin AN. Topical calcineurin inhibitors. In: Wolverton SE, editor. Comprehensive dermatologic drug therapy. 3rd ed. Edinburgh: Elsevier/Saunders; 2013. p. 535-42.
2. Maloney JM, Flores J, Sheehan M, et al. Efficacy and safety of 0.1% and 0.5% tacrolimus cream versus vehicle for treatment of mild to moderate plaque psoriasis in adults. J Am Acad Dermatol 2007;56: AB10.
3. Remitz A, Reitamo S, Erkko P, et al. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol 1999;141: 103-7, doi:10.1046/j.1365-2133.1999.02927.x. (Pubitemid 29333700)
4. Buder K, Knuschke P, Wozel G. Evaluation of methylprednisolone aceponate, tacrolimus and combination thereof in the psoriasis plaque test using sum score, 20-MHz-ultrasonography and optical coherence tomography. Int J Clin Pharmacol Ther 2010;48: 814-20.
5. Zonneveld IM, Rubins A, Jablonska S, et al. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol 1998;134: 1101-2, doi:10.1001/archderm.134.9.1101. (Pubitemid 28432323)
6. Nelson A, Krejci-Manwaring J, Fleischer A, et al. A randomized, double-blind, vehicle-controlled, right/left comparative study of the efficacy of acitretin with and without the co-administration of 0.1% tacrolimus topical ointment in the treatment of moderate to severe psoriasis. J Am Acad Dermatol 2007;56: AB181.
7. Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004;51: 723-30, doi:10.1016/j.jaad.2004.07.011. (Pubitemid 39516886)
8. Liao YH, Chiu HC, Tseng YS, et al. Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol 2007;157: 1005-12, doi:10. 1111/j.1365-2133.2007.08201.x. (Pubitemid 47583535)
9. Rajzer L, Wojas-Pelc A, Obtulowicz A. The efficacy and safety of an ointment containing 0.1% tacrolimus in facial and flexural psoriasis. J Eur Acad Dermatol 2005;19: 178.
10. He Y. Clinical efficacy of 0.1% tacrolimus ointment on plaque psoriasis of scalp and face. J Clin Dermatol 2008;37: 254-5. (Pubitemid 351722025)
11. Kleyn CE, Woodcock D, Sharpe GR. The efficacy of 0.1% tacrolimus ointment compared with clobetasone butyrate 0.05% ointment in patients with facial, flexural or genital psoriasis. Br J Dermatol 2005;153: 33.
12. Carroll CL, Clarke J, Camacho F, et al. Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol 2005;141: 43-6, doi:10.1001/archderm. 141.1.43. (Pubitemid 40144438)
13. Ortonne JP, Van de Kerkhof PC, Prinz JC, et al. 0.3% tacrolimus gel and 0.5% tacrolimus cream show efficacy in mild to moderate plaque psoriasis: results of a randomized, open-label, observerblinded study. Acta Derm Venereol 2006;86: 29-33. (Pubitemid 46939785)
14. Vissers WH, Van Vlijmen I, Van Erp PE, et al. Topical treatment of mild to moderate plaque psoriasis with 0.3%tacrolimus gel and 0.5% tacrolimus cream: the effect on SUM score, epidermal proliferation, keratinization, T-cell subsets and HLA-DR expression. Br J Dermatol 2008;158: 705-12, doi:10.1111/j.1365-2133. 2008.08442.x. (Pubitemid 351415744)
15. Tirado-Sanchez A, Ponce-Olivera RM. Preliminary study of the efficacy and tolerability of combination therapy with calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of stable plaque psoriasis. Cutis 2012;90: 140-4.
16. Rallis E, Nasiopoulou A, Kouskoukis C, et al. Successful treatment of genital and facial psoriasis with tacrolimus ointment 0.1%. Drugs Exp Clin Res 2005;31: 141-5. (Pubitemid 41415168)
17. Freeman AK, Linowski GJ, Brady C, et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 2003;48: 564-8, doi:10.1067/mjd.2003.169. (Pubitemid 36397020)
18. Yamamoto T, Nishioka K. Topical tacrolimus is effective for facial lesions of psoriasis. Acta Derm Venereol 2000;80: 451. (Pubitemid 32156234)
19. Yamamoto T, Nishioka K. Topical tacrolimus: an effective therapy for facial psoriasis. Eur J Dermatol 2003;13: 471-3. (Pubitemid 37305092)
20. Clayton TH, Harrison PV, Nicholls R, et al. Topical tacrolimus for facial psoriasis. Br J Dermatol 2003;149: 419-20, doi:10.1046/j.1365-2133.2003.05426. x.
21. Martin EG, Sanchez RM, Herrera AE, et al. Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques. J Drugs Dermatol 2006;5: 334-6.
22. Brune A, Miller DW, Lin P, et al. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol 2007;24: 76-80, doi:10.1111/j.1525-1470. 2007.00341.x.
23. Bissonnette R, Nigen S, Bolduc C. Efficacy and tolerability of topical tacrolimus ointment for the treatment of male genital psoriasis. J Cutan Med Surg 2008;12: 230-4.
24. Rivard J, Janiga J, Lim HW. Tacrolimus ointment 0.1%alone and in combination with medium-dose UVA1 in the treatment of palmar or plantar psoriasis. J Drugs Dermatol 2006;5: 505-10.
25. De Simone C, Maiorino A, Tassone F, et al. Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open-label study. J Eur Acad Dermatol Venereol 2013;8: 1003-6.
26. Nagao K, Ishiko A, Yokoyama T, et al. A case of generalized pustular psoriasis treated with topical tacrolimus. Arch Dermatol 2003;139: 1219. (Pubitemid 37128393)
27. Kroft EB, Erceg A, Maimets K, et al. Tacrolimus ointment for the treatment of severe facial plaque psoriasis. J Eur Acad Dermatol Venereol 2005;19: 249-51, doi:10.1111/j.1468-3083.2005.01122.x. (Pubitemid 40450439)
28. Carrascosa JM, Soria X, Domingo H, et al. Treatment of inverse psoriasis with excimer therapy and tacrolimus ointment. Dermatol Surg 2007;33: 361-3, doi:10.1111/j.1524-4725.2007.33074.x. (Pubitemid 46328238)
29. Sehgal VN, Sehgal S, Verma P, et al. Exclusive plaque psoriasis of the lips: efficacy of combination therapy of topical tacrolimus, calcipotriol, and betamethasone dipropionate. Skinmed 2012;10: 183-4.
30. Yamamoto T, Nishioka K. Successful treatment with topical tacrolimus for oral psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 1137-8, doi:10.1111/j.1468-3083.2006.01630.x. (Pubitemid 44425977)
31. Laino L, DiCarlo A. Palmoplantar pustular psoriasis: clinical and video thermographic evaluation before and after topical tacrolimus treatment. Arch Dermatol 2011;147: 760, doi:10.1001/archdermatol. 2011.120.
32. Rodriguez GF, Fagundo GE, Cabrera-Paz R, et al. Generalized pustular psoriasis successfully treated with topical tacrolimus. Br J Dermatol 2005;152: 587-8, doi:10.1111/j.1365-2133.2005.06468.x. (Pubitemid 40547149)
33. Rallis E, Verros CD. Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies. Dermatol Online J 2011;17: 14.
34. Steele JA, Choi C, Kwong PC. Topical tacrolimus in the treatment of inverse psoriasis in children. J Am Acad Dermatol 2005;53: 713-6, doi:10.1016/j.jaad.2005.05.036. (Pubitemid 41399952)
35. Jegasothy BV, Ackerman CD, Todo S, et al. Tacrolimus (FK 506) - a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 1992;128: 781-5, doi:10.1001/archderm.1992.01680160065005.
36. The European FK 506 Multicentre Psoriasis Study Group. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study Group. Arch Dermatol 1996;132: 419-23, doi:10.1001/archderm. 1996.03890280081011.
37. Rubins A. A double blind clinical trial of FK-506 (tacrolimus) in 16 patients with psoriasis. J Eur Acad Dermatol Venereol 1995;5 Suppl 1:S146, doi:10.1016/0926-9959(95)96361-B.
38. Bissonnette R, Papp K, Poulin Y, et al. A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. J Am Acad Dermatol 2006;54: 472-8, doi:10.1016/j.jaad.2005.10.061. (Pubitemid 43243451)
39. Papp K, Bissonnette R, Rosoph L, et al. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo- controlled phase III study. Lancet 2008;371: 1337-42, doi:10. 1016/S0140-6736(08)60593-0. (Pubitemid 351522314)
40. Mrowietz U, Graeber M, Brautigam M, et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998;139: 992-6, doi:10.1046/j.1365-2133.1998.02554.x. (Pubitemid 29010535)
41. Mrowietz U, Wustlich S, Hoexter G, et al. An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm Venereol 2003;83: 351-3, doi:10. 1080/00015550310003791. (Pubitemid 37281542)
42. Gribetz C, Ling M, Lebwohl M, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004;51: 731-8, doi:10.1016/j.jaad.2004.06.010. (Pubitemid 39516887)
43. Kreuter A, Sommer A, Hyun J, et al. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol 2006;142: 1138-43, doi:10.1001/archderm.142.9.1138. (Pubitemid 44414397)
44. Jacobi A, Braeutigam M, Mahler V, et al. Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study. Dermatology 2008;216: 133-6, doi:10.1159/000111510. (Pubitemid 351158578)
45. Mansouri P, Farshi S. Pimecrolimus 1 percent cream in the treatment of psoriasis in a child. Dermatol Online J 2006;12: 7.
46. Ahn SJ, Oh SH, Chang SE, et al. A case of infantile psoriasis with pseudoainhum successfully treated with topical pimecrolimus and low-dose narrowband UVB phototherapy. J Eur Acad Dermatol Venereol 2006;20: 1332-4, doi:10.1111/j.1468-3083. 2006.01680.x.
47. Canpolat F, Cemil BC, Tatlican S, et al. Pimecrolimus 1% cream is effective in the treatment of psoriasis in an infant. Eur J Dermatol 2009;19: 168-9.
48. Amichai B. Psoriasis of the glans penis in a child successfully treated with elidel (pimecrolimus) cream. J Eur Acad Dermatol Venereol 2004;18: 742-3, doi:10.1111/j.1468-3083.2004.01054.x. (Pubitemid 39429729)
49. Rappersberger K, Komar M, Ebelin ME, et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 2002;119: 876-87, doi:10.1046/j.1523-1747.2002. 00694.x. (Pubitemid 35340914)
50. Gottlieb AB, Griffiths CE, Ho VC, et al. Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. Br J Dermatol 2005;152: 1219-27, doi:10.1111/j.1365-2133. 2005.06661.x. (Pubitemid 40933421)
51. Griffiths C, Dubertret L, Gottlieb A. Treatment with oral pimecrolimus significantly improves psoriasis with a clear doseresponse effect [abstract]. J Invest Dermatol 2003;121: 66.